A trial of etirinotecan pegol for advanced ovarian cancer that is resistant to platinum drugs

Cancer type:

Ovarian cancer

Status:

Results

Phase:

Phase 2

This trial looked at a drug called etirinotecan pegol (also known as NKTR-102) for women with ovarian cancer. The trial was for women with

Their cancer had come back despite having other treatment and could not be removed with surgery.

These cancers are all treated in the same way, so when we use the term ovarian cancer in this summary, we are referring to all 3.

Doctors usually treat ovarian cancer with surgery followed by chemotherapy. The chemotherapy drugs they most commonly use are platinum drugs such as carboplatin. If the cancer gets worse or comes back within 6 months of finishing this type of treatment, it is called platinum resistant ovarian cancer.

Platinum resistant ovarian cancer is difficult to treat. You may have a drug called liposomal doxorubicin, but the cancer may still continue to grow.

In this trial, researchers were looking at a drug called etirinotecan pegol. It is made by joining the chemotherapy drug irinotecan with another substance called a glycol. This process is called pegylation. It helps to keep irinotecan circulating for longer. So you may get more benefit from the drug without having a higher dose.

The aims of the trial were to see if etirinotecan pegol was safe and if it helped women with platinum resistant advanced ovarian cancer.

Summary of results

The trial team found that etirinotecan pegol was safe and did help women with platinum resistant advanced ovarian cancer.  

This was a phase 2 trial. It was a randomised trial and recruited 71 women. They were put into 1 of 2 treatment groups. Neither they nor their doctor chose which group they were in. Everyone in the trial had the study treatment.

  • 36 women had etirinotecan pegol once a week every 2 weeks
  • 35 women had etirinotecan pegol once a week every 3 weeks

The average length of time before their cancer started to grow again was

  • Just over 4 months for those women who had etirinotecan pegol every 2 weeks
  • Just over 5 months for those women who had etirinotecan pegol every 3 weeks

The average overall length of time that the women lived was

  • 10 months for those who had etirinotecan pegol every 2 weeks
  • 11½ months for those who had etirinotecan pegol every 3 weeks

The women who had etirinotecan pegol every 3 weeks had fewer side effects.

The most common side effects were diarrhoea and dehydration.

The trial team concluded that etirinotecan pegol helped women who had platinum resistant ovarian cancer. Having etirinotecan pegol every 3 weeks had fewer side effects and this is the preferred way to give it for future studies.    

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Nick Reed
Professor Hilary Calvert

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Nektar Therapeutics

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 5711

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page